Sino Biopharm to fully acquire LaNova

Sino Biopharmaceutical plans to acquire the remaining 95.09% of LaNova Medicines for up to USD 951 million, raising its stake to 100%. After accounting for LaNova’s estimated USD 450 million in cash, the net payment will be about USD 500 million. The deal strengthens Sino Biopharm’s pipeline as it targets the launch of 30 new drugs by 2027.